SLITRK5 is a cellular protein whose normal function appears to suppress bone formation and could be a potential new target for the treatment ofosteoporosis, according to a collaborative study conducted by Weill Cornell Medicine and NewYork-Presbyterian researchers.
Cells manifesting the SLITRK5 protein are marked with magenta (left) and a bone-forming osteoblast marker in green (center). These markers were observed in the cancellous bone in the medulla space (top) or on the outer layer covering the bone (bottom). The overlap between these two markers (right) shows that SLITRK5 is found in bone-forming osteoblasts but not in other cell types, helping to make SLITRK5 a target for skeletal disease treatment. Credit: Dr. Matthew Greenblatt and Dr. Jun Sun
There Research was published in the scientific journal Nature Communications.
Read Also
- Messi’s talk with Ibai: “We went from sadness to joy in a couple of days” Aug 11, 2021
- Cloud storage that encrypts your files so they’re safe May 31, 2021
- Marseille: An expert appointed to rule on excessive heat at Baumettes in the summer Nov 15, 2022
- Gray hair: the cause is stress, but it is reversible Jul 3, 2021
- Employers complaining about delays to business aid payments Aug 29, 2021
- “Ocean Viking”: More migrants in the Giens waiting area Nov 24, 2022
- Microsoft wants to eliminate passwords: what will the alternative to access Outlook be like Sep 16, 2021